Volume 2, Issue 2 (Winter 2010)                   Iranian Journal of Blood and Cancer 2010, 2(2): 71-76 | Back to browse issues page

XML Print


Abstract:   (12013 Views)

Hematopoietic stem cell transplantation (HSCT) has been practiced for more than 30 years. Hematological malignancies
are the main indications for this treatment. However, its indications in adults are different from children.
Advances in chemotherapy and target therapy have improved treatment outcome of some of the very high risk
cancers, and changed indications of HSCT in children. Multi-center clinical trials evaluating outcome of childhood
cancers using different therapeutic protocols are needed to precisely define the role of HSCT. A review on the current
literature about HSCT indications in pediatric cancers is presented in this manuscript.

Full-Text [PDF 787 kb]   (8569 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2011/03/12 | Published: 2010/02/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.